Ferrières L, et al. - Researchers conducted a retrospective study to assess the incidence, causes and factors of secukinumab discontinuation in patients with psoriasis in order to better determine the real-life maintenance of secukinumab in psoriasis. From September 2011 to June 2017, all patients treated with secukinumab for psoriasis were included in the Dermatology Department of Toulouse, France. Secukinumab's long-term persistence seems to be good, with only 22 (24, 2%) patients discontinuing secukinumab over the follow-up period. Loss of effectiveness concerns about 14% at 2 years of age of patients. Persistence in patients with palmoplantar psoriasis and patients previously exposed to many systemic therapies appears to be lower. Optimal therapeutic response at 12-16 weeks as defined by achieving PASI 90-100 appears to predict persistence of long-term therapy. Longer duration of the disease and psoriasis of palmoplantar appear to be predictive factors for failure of treatment.